RKLB, ASTS, LUNR, SATS Stocks ‘Primed To Soar’ On SpaceX ‘Monster’ IPO Ripple Effect, Says Veteran Trader

ASTS, RKLB and LUNR continued drawing attention through satellite rollouts, launch programs, and NASA contracts.
The SpaceX logo is displayed on a smartphone screen with the Cursor logo in the background, as SpaceX announces a partnership with Cursor, in Creteil, France, on April 22, 2026. (Photo by Samuel Boivin/NurPhoto via Getty Images)
The SpaceX logo is displayed on a smartphone screen with the Cursor logo in the background, as SpaceX announces a partnership with Cursor, in Creteil, France, on April 22, 2026. (Photo by Samuel Boivin/NurPhoto via Getty Images)
Profile Image
Deepti Sri·Stocktwits
Published May 19, 2026   |   11:34 PM EDT
Share
·
Add us onAdd us on Google
Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...
  • Najarian called SpaceX a “$1.75T monster” and said RKLB, ASTS, LUNR, and “the rest of the space crew are primed to soar.”
  • SpaceX could reportedly file publicly for its IPO as soon as this week, ahead of a possible June Nasdaq listing under the ticker “SPCX.”
  • Goldman Sachs and Morgan Stanley reportedly secured top positions on SpaceX’s IPO prospectus.

Shares of Rocket Lab (RKLB), AST SpaceMobile (ASTS), Intuitive Machines (LUNR) and EchoStar (SATS) are in focus late Tuesday as veteran trader Jon Najarian said that SpaceX’s potential $1.75 trillion valuation could trigger a massive ripple effect across the broader space trade.

On Tuesday, ASTS gained over 1%, while RKLB and LUNR fell around 3%. SATS traded nearly flat. 

Read Next
Loading...
Loading...

Investor Calls SpaceX A ‘$1.75T Monster’

“Space is heating up!” Najarian, a former Chicago Board Options Exchange floor trader, said on X. “SpaceX eyeing $1.5T–$1.75T valuation — already double where it was, and richly priced,” he said.  

While cautioning that “quick doubles” may require patience, the investor said the “ripple effect is massive,” adding that RKLB, ASTS, LUNR and “the rest of the space crew are primed to soar as headlines stay locked on this $1.75T monster.” “Space bulls — this is your decade,” he added.

Investor excitement across the space sector has intensified as SpaceX moves closer to what could be the largest IPO in Wall Street history. The Elon Musk-led rocket, satellite, and AI giant could reportedly publicly file for its IPO as soon as this week, ahead of a potential June 12 Nasdaq listing under the ticker “SPCX.” SpaceX is reportedly targeting a valuation north of $2 trillion while seeking to raise up to $75 billion.

Meanwhile, Goldman Sachs has reportedly secured the leading position on the cover of SpaceX’s IPO prospectus, alongside Morgan Stanley. Bank of America, Citigroup and JPMorgan Chase were also apparently listed among the lead banks tied to the offering.

SpaceX Catalysts

The frenzy accelerated further as investors viewed SpaceX not just as a rocket and satellite company, but as a growing AI player. SpaceX reportedly expects to move ahead with its acquisition of AI coding startup Cursor 30 days after the IPO. The company had apparently secured the right to acquire Cursor for $60 billion later this year, or to pay a $10 billion breakup fee tied to the partnership.

Focus has also turned to SpaceX’s upcoming Starship V3 launch, which is viewed as one of the company’s most important pre-IPO catalysts. The upgraded fully reusable rocket is expected to feature improvements in payload capacity, heat-shield systems, propellant transfer capabilities and orbital refueling architecture for future Moon and Mars missions. Investors are also watching whether Starship V3 can validate SpaceX’s strategy to lower launch costs and scale Starlink deployment.

ASTS, RKLB, LUNR, SATS Stocks Ride SpaceX Buzz

AST SpaceMobile recently began shipping its next BlueBird Block 2 satellites to Cape Canaveral, while CEO Abel Avellan reiterated the company remains on track to deploy 45 satellites this year despite recent launch setbacks. Investors are also closely watching AST’s direct-to-device broadband plans as the company positions itself against Starlink in satellite-based mobile connectivity.

Rocket Lab has continued expanding its launch pipeline through new Electron missions and orbital infrastructure programs, while its focus remains on its larger Neutron rocket, viewed as one of the clearest emerging commercial launch challengers to SpaceX.

Meanwhile, Intuitive Machines recently secured new NASA lunar reconnaissance contracts and ended the first quarter with a record $1.1 billion backlog, boosting investor optimism around the company’s growing role in lunar infrastructure and space-defense programs.

Last week, New Street Research launched coverage on Rocket Lab, Viasat and EchoStar with ‘Buy’ ratings. The firm said Rocket Lab’s valuation still implies the company captures less than 1% of the broader space economy opportunity despite being “the only scaled Western platform outside of SpaceX.” New Street also called EchoStar a “proxy play” on SpaceX due to its expected equity exposure from the companies’ spectrum transaction.

How Do Retail Traders Feel About Space Stocks?

On Stocktwits, retail sentiment around ASTS, LUNR and SATS was ‘extremely bullish,’ with LUNR and SATS seeing ‘extremely high’ message volume and ASTS recorded ‘normal’ chatter levels. Meanwhile, RKLB retail sentiment was ‘bearish’ amid ‘high’ message volume. 

One bullish user said, “$RKLB makes me laugh why ppl would sell so deeply in the red,  this is going down no news, as well. Still cheap if you think space x is 5x value and yet rklb is second to them, won't be long till there challenging up rklb I buy more.”

Another user said, “Most people think SpaceX's $1.75 trillion valuation is about rockets, but the real engine driving the largest IPO in history is Starlink.”

Over the past year, SATS surged 521%, RKLB jumped 393%, ASTS climbed 256% and LUNR gained 168%.

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Read Next: IBRX Stock Jumps Overnight After Major FDA Review Win For Anktiva In Bladder Cancer 

Follow on Google News
Read about our editorial guidelines and ethics policy